Waldenstrom's Macroglobulinemia Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.A Phase 1 Dose-Escalation and Expansion Study of BGB-16673 in Patients With B-Cell Malignancies
Conditions: B-cell Malignancy; Marginal Zone Lymphoma; Follicular Lymphoma; Non-hodgkin Lymphoma; Waldenström Macroglobulinemia Intervention: Drug: BGB-16673 Sponsor: BeiGene Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 16, 2021 Category: Research Source Type: clinical trials
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
Conditions: Follicular Lymphoma; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Waldenstrom Macroglobulinemia; Marginal Zone Lymphoma; Mantle Cell Lymphoma; Indolent Lymphoma; Refractory B-Cell Lymphoma; MALT Lymphoma Intervention: Drug: PSB202 Sponsor: Qilu Puget Sound Biotherapeutics (dba Sound Biologics) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 12, 2021 Category: Research Source Type: clinical trials
